ArticleHealth science reports2026
From Tumor Marker to Congestion Indicator: The Expanding Role of CA-125 in Heart Failure and Beyond.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: To evaluate the transition of Carbohydrate antigen 125 (CA-125) from an ovarian tumor marker to a versatile indicator of systemic congestion and fluid overload. Methods: A literature review (1984-2025) was conducted using PubMed, Scopus, and Web of Science. Keywords included "CA-125," "systemic congestion," and related terms. Studies on the diagnostic and prognostic value of CA-125 in congestive disorders were analyzed. Results: CA-125 is synthesized by mesothelial cells in response to mechanical stress and inflammation, particularly via c-Jun N-terminal kinase (JNK) signaling pathways. It provides significant prognostic value in heart failure (HF), renal failure, and cirrhosis, often rivaling or complementing NT-proBNP. Conclusion: CA-125 is a versatile biomarker for systemic congestion, offering diagnostic and prognostic value across cardiology, nephrology, and hepatology. Refining its clinical application could optimize fluid management in diverse patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.